Transcription factors as therapeutic targets in CNS disorders

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 3, 2009, Pages 190-199

  Kane, Michael J ^a   Citron, Bruce A ^b  

^a Bay Pines VA Healthcare System   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AP 1; Apoptosis; c Jun; Inflammatory response; Ischemia; JNK; Neurodegenerative diseases; Neurons; Nrf2; p53; PPAR; Sp1; Spinal cord injury; Transcription factors; Traumatic brain injury

Indexed keywords

7 AZAINDOLE DERIVATIVE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHROMOMYCIN A3; CIGLITAZONE; FENOFIBRATE; GLYCOGEN SYNTHASE KINASE 3BETA; INDOLE; METHYLPHENIDATE; MITHRAMYCIN; MITHRAMYCIN A; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIFITHRIN ALPHA; PIOGLITAZONE; PROTEIN C JUN; PROTEIN P53; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; SULFORAPHANE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SP1; TROGLITAZONE; UNCLASSIFIED DRUG;

BRAIN INFARCTION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; EYE DISEASE; GENE EXPRESSION; GLAUCOMA; HORMONAL REGULATION; HUMAN; ISCHEMIA; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SHY DRAGER SYNDROME; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; APOPTOSIS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; PATENTS AS TOPIC; TRANSCRIPTION FACTORS;

EID: 70449511627     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909789104820     Document Type: Review

References (149)

1. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: A randomised controlled trial. Lancet Neurol 2007; 6(1): 29-38. (Pubitemid 44880259)
2. Citron BA, Dennis JS, Zeitlin RS, Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res 2008; 86(11): 2499-2504.
3. Eve DJ, Dennis JS, Citron BA. Transcription factor p53 in degenerating spinal cords. Brain Res 2007; 1150: 174-181. (Pubitemid 46702113)
4. Marciano PG, Eberwine JH, Ragupathi R, Saatman KE, Meaney DF, McIntosh TK. Expression profiling following traumatic brain injury: A review. Neurochem Res 2002; 27(10): 1147-1155. (Pubitemid 35316111)
5. Pennypacker KR, Kassed CA, Eidizadeh S, O'Callaghan JP. Brain injury: Prolonged induction of transcription factors. Acta Neurobiol Exp (Wars) 2000; 60(4): 515-530.
6. Nonaka M, Chen XH, Pierce JE, et al. Prolonged activation of NF-kappaB following traumatic brain injury in rats. J Neurotrauma 1999; 16(11): 1023-1034.
7. Nurmi A, Vartiainen N, Pihlaja R, Goldsteins G, Yrjanheikki J, Koistinaho J. Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window. J Neurochem 2004; 91(3): 755-765. (Pubitemid 39431168)
8. Francis JS, Dragunow M, During MJ. Over expression of ATF-3 protects rat hippocampal neurons from in vivo injection of kainic acid. Brain Res Mol Brain Res 2004; 124(2): 199-203. (Pubitemid 38591572)
9. Li F, Hayashi T, Jin G, et al. The protective effect of dantrolene on ischemic neuronal cell death is associated with reduced expression of endoplasmic reticulum stress markers. Brain Res 2005; 1048(1-2): 59-68. (Pubitemid 40800260)
10. Dash PK, Moore AN, Dixon CE. Spatial memory deficits, increased phosphorylation of the transcription factor CREB, and induction of the AP-1 complex following experimental brain injury. J Neurosci 1995; 15(3 Pt 1): 2030-2039.
11. Sama MA, Mathis DM, Furman JL, et al. Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. J Biol Chem 2008; 283(32): 21953-21964.
12. Humar M, Graetz C, Roesslein M, et al. Heterocyclic thioureylenes protect from calcium-dependent neuronal cell death. Mol Pharmacol 2009; 75(3): 667-676.
13. Benedito AB, Lehtinen M, Massol R, et al. The transcription factor NFAT3 mediates neuronal survival. J Biol Chem 2005; 280(4): 2818-2825. (Pubitemid 40189389)
14. Zhang X, Chen Y, Ikonomovic MD, et al. Increased phosphorylation of protein kinase B and related substrates after traumatic brain injury in humans and rats. J Cereb Blood Flow Metab 2006; 26(7): 915-926. (Pubitemid 43980408)
15. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22(56): 9030-9040.
16. Slee EA, O'Connor DJ, Lu X. To die or not to die: How does p53 decide? Oncogene 2004; 23(16): 2809-2818.
17. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 2005; 331(3): 761-777.
18. Morrison RS, Kinoshita Y, Johnson MD, Guo W, Garden GA. p53-dependent cell death signaling in neurons. Neurochem Res 2003; 28(1): 15-27. (Pubitemid 36173223)
19. Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Dis 2000; 7(6 Pt B): 613-622.
20. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002; 156(3): 519-529. (Pubitemid 34839899)
21. Uberti D, Lanni C, Carsana T, et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 2006; 27(9): 1193-1201. (Pubitemid 44067307)
22. Cuesta A, Zambrano A, Royo M, Pascual A. The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem J 2009; 418(3): 643-650.
23. Nair VD. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis 2006; 11(6): 955-966.
24. Duan W, Zhu X, Ladenheim B, et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52(5): 597-606. (Pubitemid 35246863)
25. Feng Z, Jin S, Zupnick A, et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 2006; 25(1): 1-7. (Pubitemid 43049998)
26. Bae BI, Xu H, Igarashi S, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005; 47(1): 29-41. (Pubitemid 40922848)
27. Culmsee C, Zhu X, Yu QS, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001; 77(1): 220-228. (Pubitemid 32245096)
28. Leker RR, Aharonowiz M, Greig NH, Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: Effects of the p53 inhibitor pifithrin alpha. Exp Neurol 2004; 187(2): 478-486. (Pubitemid 38610294)
29. Crumrine RC, Thomas AL, Morgan PF. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J Cereb Blood Flow Metab 1994; 14(6): 887-891.
30. Gudkov, A.V., Komarov, P.G., Komarova, E.A.: WO00044364 (2000).
31. Greig, N.H., Mattson, M., Zhu, X., Yu, Q.-S., Holloway, H.W.: WO2002004409 (2002).
32. Zhou, M.M., Sachchidanand, D., Zeng, L., Manfredi, J.J., Resnick-Silverman, L., Aaronson, S.: WO2007084625 (2007).
33. Ratan, R.R., Chatterjee, S.: WO2002015912 (2002).
34. Rohr, J., Baig, I., Salas-Fernández, J.A., Fernández- Braña, A., Méndez-Fernández, C., Pérez-Solares, M.: WO2008096028 (2008).
35. Xigen, S.A., Bonny, C.: WO2007031098 (2007).
36. Pang, I.H., Clark, A.F.: WO2006050045 (2006).
37. Zeldis, J.B., Faleck, H., Manning, D.: WO2006058007 (2006).
38. He, Z., Yiu, G.: WO2008024776 (2008).
39. Pellecchia, M.: WO2008118626 (2008).
40. Graczyk, P.P., Dimopoulas, P., Farthing, C.N., Bhatia, G.S., Khan, A.: WO2008095943 (2008).
41. Watt, P., Milech, N., Fear, M.: WO2008034161 (2008).
42. Pershadsingh, H.A.: WO2002013812 (2002).
43. Avery, M.A., Pershadsingh, H.A.: WO2005009437 (2005).
44. Zhang, Y., Ho, T., Li, Y.: WO2002002190 (2002).
45. Biswal, S., Dore, S., Thimmulappa, R.K., Rangasamy, T., Sakata, Y., Shah, Z.A., Zhuang, H., Singh, A.: WO2007005879 (2007).
46. Ting, J.P.Y., Clements, C.: WO2007008652 (2007).
47. Martínez-Gil, A., Castro, M.A., Medina, P.M., Martín, A.E., Alonso, C.M., Fuertes, H.A., Navarro, R.M.L., Pérez, P.M.J., Del, M.M.M.: WO2007125109 (2007).
48. Saito N, Yamamoto T, Watanabe T, Abe Y, Kumagai T. Implications of p53 protein expression in experimental spinal cord injury. J Neurotrauma 2000; 17(2): 173-182. (Pubitemid 30120306)
49. Martin LJ, Liu Z. Injury-induced spinal motor neuron apoptosis is preceded by DNA single-strand breaks and is p53- and Bax-dependent. J Neurobiol 2002; 50(3): 181-197. (Pubitemid 34131050)
50. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285(5434): 1733-1737.
51. Zhu X, Yu QS, Cutler RG, et al. Novel p53 inactivators with neuroprotective action: Syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7- hexahydrobenzoxazole derivatives. J Med Chem 2002; 45(23): 5090-5097.
52. Sachchidanand, Resnick-Silverman L, Yan S, et al. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem Biol 2006; 13(1): 81-90. (Pubitemid 43099926)
53. Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983; 35(1): 79-87. (Pubitemid 14240221)
54. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987; 51(6): 1079-1090.
55. Kaczynski J, Cook T, Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol 2003; 4(2): 206.
56. Hirano F, Tanaka H, Hirano Y, et al. Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Mol Cell Biol 1998; 18(3): 1266-1274. (Pubitemid 28100890)
57. Bargonetti J, Chicas A, White D, Prives C. p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cell Mol Biol (Noisyle-grand) 1997; 43(7): 935-949.
58. Dhar SK, Xu Y, Chen Y, St Clair DK. Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. J Biol Chem 2006; 281(31): 21698-21709. (Pubitemid 44181873)
59. Gill G, Pascal E, Tseng ZH, Tjian R. A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci USA 1994; 91(1): 192-196. (Pubitemid 24018669)
60. Marin M, Karis A, Visser P, Grosveld F, Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 1997; 89(4): 619-628. (Pubitemid 27511772)
61. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344 Pt 2: 305-311. (Pubitemid 30011584)
62. Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci 1997; 17(19): 7415-7424. (Pubitemid 27413272)
63. Liu W, Wang G, Yakovlev AG. Identification and functional analysis of the rat caspase-3 gene promoter. J Biol Chem 2002; 277(10): 8273-8278. (Pubitemid 34968286)
64. Lee J, Kosaras B, Aleyasin H, et al. Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response. FASEB J 2006; 20(13): 2375-2377. (Pubitemid 44953832)
65. Minc E, de Coppet P, Masson P, et al. The human copper-zinc superoxide dismutase gene (SOD1) proximal promoter is regulated by Sp1, Egr-1, and WT1 via non-canonical binding sites. J Biol Chem 1999; 274(1): 503-509. (Pubitemid 29035089)
66. Lukiw WJ, Rogaev EI, Wong L, Vaula G, McLachlan DR, St George Hyslop P. Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Brain Res Mol Brain Res 1994; 22(1-4): 121-131. (Pubitemid 24063632)
67. Querfurth HW, Jiang J, Xia W, Selkoe DJ. Enhancer function and novel DNA binding protein activity in the near upstream betaAPP gene promoter. Gene 1999; 232(1): 125-141. (Pubitemid 29305325)
68. Docagne F, Gabriel C, Lebeurrier N, et al. Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J 2004; 383(Pt 2): 393-399. (Pubitemid 39446701)
69. Heicklen-Klein A, Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 2000; 75(4): 1408-1418. (Pubitemid 30694656)
70. Renbaum P, Beeri R, Gabai E, et al. Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. Gene 2003; 318: 113-124. (Pubitemid 37338397)
71. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 2004; 24(2): 865-874. (Pubitemid 38057936)
72. Ryu H, Lee J, Olofsson BA, et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 2003; 100(7): 4281-4286. (Pubitemid 36418194)
73. Li SH, Cheng AL, Zhou H, et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 2002; 22(5): 1277-1287. (Pubitemid 34150765)
74. Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002; 296(5576): 2238-2243. (Pubitemid 34680312)
75. Qiu Z, Norflus F, Singh B, et al. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 2006; 281(24): 16672-16680. (Pubitemid 43909622)
76. Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 2001; 49(3): 345-354. (Pubitemid 32202788)
77. Ferrante RJ, Ryu H, Kubilus JK, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 2004; 24(46): 10335-10342. (Pubitemid 39552617)
78. Perez M, Baig I, Brana AF, Salas JA, Rohr J, Mendez C. Generation of new derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosynthesis. Chembiochem 2008; 9(14): 2295-2304.
79. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85(2-5): 267-273. (Pubitemid 37011102)
80. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta 2007; 1771(8): 1031-1045.
81. Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 2003; 71(3): 315-325. (Pubitemid 36159491)
82. Bordet R, Gele P, Duriez P, Fruchart JC. PPARs: A new target for neuroprotection. J Neurol Neurosurg Psychiatry 2006; 77(3): 285-287.
83. Bordet R, Ouk T, Petrault O, et al. PPAR: A new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006; 34(Pt 6): 1341-1346. (Pubitemid 46769051)
84. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004; 24(48): 10908-10917. (Pubitemid 39602402)
85. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000; 20(2): 558-567.
86. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: Associated with iNOS and COX-2. Brain Res 2002; 941(1-2): 1-10.
87. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 2005; 280(22): 21453-21462. (Pubitemid 40805710)
88. Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005; 128(Pt 6): 1442-1453. (Pubitemid 40826196)
89. Zhao X, Ou Z, Grotta JC, Waxham N, Aronowski J. Peroxisomeproliferator- activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res 2006; 1073-1074: 460-469.
90. Bernardo A, Gasparini L, Ongini E, Minghetti L. Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: Implications for chronic treatments of neurodegenerative diseases. Neurobiol Dis 2006; 22(1): 25-32.
91. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82(3): 615-624. (Pubitemid 34831499)
92. Deplanque D, Gele P, Petrault O, et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003; 23(15): 6264-6271. (Pubitemid 36875628)
93. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 2005; 388(1): 7-12. (Pubitemid 41569361)
94. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008; 1244: 164-172.
95. Hyong A, Jadhav V, Lee S, et al. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 2008; 1215: 218-224.
96. Luo Y, Yin W, Signore AP, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97(2): 435-448.
97. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neurosci 2005; 130(3): 685-696. (Pubitemid 39601441)
98. Shimazu T, Inoue I, Araki N, et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005; 36(2): 353-359. (Pubitemid 40170822)
99. Park SW, Yi JH, Miranpuri G, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007; 320(3): 1002-1012. (Pubitemid 46294061)
100. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 1994; 91(21): 9926-9930. (Pubitemid 24311921)
101. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:Quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996; 93(25): 14960-14965. (Pubitemid 26419078)
102. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991; 266(18): 11632-11639.
103. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13(1): 76-86. (Pubitemid 29045117)
104. Itoh K, Ishii T, Wakabayashi N, Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res 1999; 31(4): 319-324. (Pubitemid 29452857)
105. Johnson JA, Johnson DA, Kraft AD, et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008; 1147: 61-69.
106. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003; 278(14): 12029-12038. (Pubitemid 36800179)
107. Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004; 24(5): 1101-1112.
108. Shih AY, Li P, Murphy TH. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 2005; 25(44): 10321-10335. (Pubitemid 41636229)
109. Jakel RJ, Townsend JA, Kraft AD, Johnson JA. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007; 1144: 192-201.
110. Zhao J, Kobori N, Aronowski J, Dash PK. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 2006; 393(2-3): 108-112. (Pubitemid 41821089)
111. Zhao X, Sun G, Zhang J, et al. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke 2007; 38(12): 3280-3286. (Pubitemid 350175749)
112. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008; 28(50): 13574-13581.
113. Burton NC, Kensler TW, Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006; 27(6): 1094-1100.
114. Shih AY, Erb H, Murphy TH. Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. J Neurochem 2007; 101(1): 109-119. (Pubitemid 46426469)
115. Chen PC, Vargas MR, Pani AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA 2009; 106(8): 2933-2938.
116. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299(5604): 256-259. (Pubitemid 36131051)
117. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006; 103(41): 15091-15096.
118. Rojo AI, Sagarra MR, Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: Relevance to exposure of neuronal cells to oxidative stress. J Neurochem 2008; 105(1): 192-202.
119. Hamann M, Alonso D, Martin-Aparicio E, et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod 2007; 70(9): 1397-1405. (Pubitemid 47584577)
120. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27(48): 6245-6251.
121. Waetzig V, Herdegen T. Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci Lett 2004; 361(1-3): 64-67. (Pubitemid 38609217)
122. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410(6824): 37-40. (Pubitemid 32225829)
123. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103(2): 239-252.
124. Bjorkblom B, Vainio JC, Hongisto V, Herdegen T, Courtney MJ, Coffey ET. All JNKs can kill, but nuclear localization is critical for neuronal death. J Biol Chem 2008; 283(28): 19704-19713.
125. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 1998; 95(18): 10541-10546. (Pubitemid 28413103)
126. Raivich G, Behrens A. Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain. Prog Neurobiol 2006; 78(6): 347-363. (Pubitemid 43850102)
127. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001; 4(4): 253-267. (Pubitemid 34456379)
128. Borsello T, Forloni G. JNK signalling: A possible target to prevent neurodegeneration. Curr Pharm Des 2007; 13(18): 1875-1886. (Pubitemid 47010160)
129. Hidding U, Mielke K, Waetzig V, et al. The c-Jun N-terminal kinases in cerebral microglia:Iimmunological functions in the brain. Biochem Pharmacol 2002; 64(5-6): 781-788. (Pubitemid 35232251)
130. Barone MC, Desouza LA, Freeman RS. Pin1 promotes cell death in NGF-dependent neurons through a mechanism requiring c-Jun activity. J Neurochem 2008; 106(2): 734-745.
131. Mei Y, Yuan Z, Song B, et al. Activating transcription factor 3 upregulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neurosci 2008; 151(3): 771-779.
132. Coffey ET, Smiciene G, Hongisto V, et al. c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J Neurosci 2002; 22(11): 4335-4345. (Pubitemid 37465649)
133. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98(24): 13681-13686.
134. Guan QH, Pei DS, Liu XM, Wang XT, Xu TL, Zhang GY. Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis. Brain Res 2006; 1092(1): 36-46.
135. Wang W, Shi L, Xie Y, et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res 2004; 48(2): 195-202. (Pubitemid 38096401)
136. Peng J, Mao XO, Stevenson FF, Hsu M, Andersen JK. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 2004; 279(31): 32626-32632. (Pubitemid 39014720)
137. Yin KJ, Kim GM, Lee JM, He YY, Xu J, Hsu CY. JNK activation contributes to DP5 induction and apoptosis following traumatic spinal cord injury. Neurobiol Dis 2005; 20(3): 881-889. (Pubitemid 41619363)
138. Dragunow M, Beilharz E, Sirimanne E, et al. Immediate-early gene protein expression in neurons undergoing delayed death, but not necrosis, following hypoxic-ischaemic injury to the young rat brain. Brain Res Mol Brain Res 1994; 25(1-2): 19-33. (Pubitemid 24223259)
139. Kindy MS, Carney JP, Dempsey RJ, Carney JM. Ischemic induction of protooncogene expression in gerbil brain. J Mol Neurosci 1991; 2(4): 217-228.
140. Kobori N, Clifton GL, Dash P. Altered expression of novel genes in the cerebral cortex following experimental brain injury. Brain Res Mol Brain Res 2002; 104(2): 148-158.
141. Raghupathi R, McIntosh TK, Smith DH. Cellular responses to experimental brain injury. Brain Pathol 1995; 5(4): 437-442.
142. Wagner AK, Drewencki LL, Chen X, et al. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury. J Neurochem 2009; 108(4): 986-997.
143. Gillardon F, Klimaschewski L, Wickert H, Krajewski S, Reed JC, Zimmermann M. Expression pattern of candidate cell death effector proteins Bax, Bcl-2, Bcl-X, and c-Jun in sensory and motor neurons following sciatic nerve transection in the rat. Brain Res 1996; 739(1-2): 244-250. (Pubitemid 26387382)
144. Schenkel J. Activation of the c-Jun transcription factor following neurodegeneration in vivo. Neurosci Lett 2004; 361(1-3): 36-39. (Pubitemid 38609210)
145. Jenkins R, Hunt SP. Long-term increase in the levels of c-jun mRNA and jun protein-like immunoreactivity in motor and sensory neurons following axon damage. Neurosci Lett 1991; 129(1): 107-110.
146. Crocker SJ, Lamba WR, Smith PD, et al. c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci USA 2001; 98(23): 13385-13390.
147. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK. Targeting the JNK MAPK cascade for inhibition: Basic science and therapeutic potential. Biochim Biophys Acta 2004; 1697(1-2): 89-101. (Pubitemid 38326764)
148. Stebbins JL, De SK, Machleidt T, et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci USA 2008; 105(43): 16809-16813.
149. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 1998; 281(5383): 1671-1674. (Pubitemid 28435582)